世界の医療用分析試験サービス市場(~2027年):種類別(バイオマーカー試験、安定性試験、原材料試験、バッチリリース試験、洗浄検証)、エンドユーザー別(製薬企業、医療機器企業、CRO)

【英語タイトル】Healthcare Analytical Testing Services Market by Type (Biomarker Testing, Stability Testing, Raw Material Testing, Batch-release Testing, Cleaning Validation, End User (Pharmaceutical Companies, Medical Device Companies, CRO) - Global Forecast to 2027

MarketsandMarketsが出版した調査資料(AST4341-23)・商品コード:AST4341-23
・発行会社(調査会社):MarketsandMarkets
・発行日:2022年12月20日
・ページ数:399
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:産業機械
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

MarketsandMarkets社は、世界の医療用分析試験サービス市場規模が2022年65億ドルから2027年111億ドルに達し、予測期間中に年平均11.4%で成長すると予測しています。本調査レポートでは、医療用分析試験サービスの世界市場を調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別(バイオマーカー試験サービス、安定性試験サービス、原材料試験サービス、バッチリリース試験サービス、洗浄検証サービス)分析、エンドユーザー別(製薬企業&バイオ医薬品企業、医療機器企業、受託研究機関)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況、企業情報などの項目を掲載しています。なお、当書に掲載されている企業情報には、Eurofins Scientific (Luxembourg)、Laboratory Corporation of America Holdings (US)、SGS S.A. (Switzerland)、Charles River Laboratories (US)、WuXi AppTec Co. Ltd. (China)、Element Materials Technology (UK)、Thermo Fisher Scientific,Inc. (US)、Pace Analytical Services LLC (US)、Intertek Group LLC (UK)、IQVIA Inc. (US)などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の医療用分析試験サービス市場規模:種類別
- バイオマーカー試験サービスの市場規模
- 安定性試験サービスの市場規模
- 原材料試験サービスの市場規模
- バッチリリース試験サービスの市場規模
- 洗浄検証サービスの市場規模
・世界の医療用分析試験サービス市場規模:エンドユーザー別
- 製薬企業&バイオ医薬品企業における市場規模
- 医療機器企業における市場規模
- 受託研究機関における市場規模
・世界の医療用分析試験サービス市場規模:地域別
- 北米の医療用分析試験サービス市場規模
- ヨーロッパの医療用分析試験サービス市場規模
- アジア太平洋の医療用分析試験サービス市場規模
- 中南米の医療用分析試験サービス市場規模
- 中東・アフリカの医療用分析試験サービス市場規模
・競争状況
・企業情報


“医療用分析試験サービス市場は、2022年の65億米ドルから2027年には111億米ドルに達し、年平均成長率は11.4%と予測”
同市場の成長を牽引しているのは、製薬会社や医療機器会社による分析試験のアウトソーシング傾向の高まりであり、研究開発費の増加も市場成長を後押ししています。しかし、熟練した専門家の不足、コストの上昇、市場プレイヤー間の圧力上昇につながる激しい市場競争は、ある程度まで市場成長を抑制する可能性があります。

“バイオ分析試験サービスは予測期間中に最も高い成長を記録する見込み”
医療用分析試験サービス市場は、タイプ別に、バイオ分析試験、物理的特性評価、メソッド開発&バリデーション、安定性試験、バッチリリース試験、原材料試験、微生物試験、環境モニタリングサービスに区分されます。バイオ分析試験サービス分野は、予測期間中に最も高い成長を記録する見込みです。この分野の高成長は、医薬品開発段階における分析試験サービスのアウトソーシング需要の増加や、製薬会社が規制当局の承認を取得するためのバリデーションサービスに起因しています。

“予測期間中に最も高いCAGRを記録する免疫原性・中和抗体検査セグメント”
バイオ分析試験サービス市場は、タイプ別に、細胞ベースアッセイ、ウイルス学試験、バイオマーカー試験、免疫原性&中和抗体試験、薬物動態試験、その他のバイオ分析試験サービスに区分されます。予測期間中に最も高い成長を記録するのは免疫原性・中和抗体検査分野です。この市場の成長は、医薬品開発と承認プロセスにおける重要性に起因しています。臨床開発においては、タンパク質治療薬に対する不要な免疫反応を注意深く監視する必要があります。その結果、免疫原性試験は、規制当局の承認を取得し、ヒトへの使用の安全性を確保するために必須となります。

“予測期間中に最も高い成長を記録する医療機器企業セグメント”
医療用分析試験サービス市場は、エンドユーザー別に製薬・バイオ製薬企業、医療機器企業、医薬品開発業務受託機関(CRO)に区分されます。医療機器企業セグメントは、予測期間中に最も高いCAGRで成長する見込みです。このセグメントの高い成長率は、医療機器企業における医療用分析試験サービスの需要に起因しています。

” APACは予測期間中に最も高いCAGRで成長する見込み ”
医療用分析試験サービス市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに区分されます。アジア太平洋地域は予測期間中に最も高いCAGRで成長する見込みです。この市場の高い成長率は、APAC諸国における有能な研究者の数の多さ、運営コストの低さ、および同地域における製薬・バイオ医薬品産業の急成長に起因しています。

本レポートで参照した医療用分析試験サービス市場の主要参入企業の内訳は以下の通りです:
- 企業タイプ別 企業タイプ別:Tier 1-35%、Tier 2-45%、Tier 3-20%
- 役職別 Cレベル-35%、ディレクターレベル-25%、その他-40%
- 地域別 北米-45%、欧州-30%、アジア太平洋地域-20%、ラテンアメリカ-3%、中東・アフリカ-2%

医療用分析試験サービスの世界市場における主要企業は、Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group LLC (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), Syneos Health, INC (US), Medpace Holdings, Inc. (US), LGC Limited (Cinven) (UK), Parexel International Corporation (US), Celerion (US). Absorption Systems LLC (US), and BioAgilytix Labs (US)です。

調査範囲
本レポートでは、さまざまな医療用分析試験サービスの市場とその導入パターンを分析しました。医療用分析試験サービスの市場規模や今後の成長性、タイプ別、エンドユーザー別、地域別などさまざまなセグメントを推定することを目的としています。また、同市場における主要企業の会社概要、サービス、最新動向とともに、詳細な競合分析も掲載しています。

レポート購入の理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業も市場の動向を把握するのに役立ち、ひいては、より大きなシェアを獲得するのに役立ちます。本レポートを購入された企業は、市場での存在感を高めるために、以下の5つの戦略のいずれか、または任意の組み合わせを使用することができます。

本レポートでは、以下のポイントに関する洞察を提供しています:
- 市場参入: 医療用分析試験サービスの世界市場におけるトップ企業が提供するサービスポートフォリオに関する包括的な情報。
- サービス開発/イノベーション: 世界の医療用分析試験サービス市場における今後の動向やサービス開始に関する詳細な洞察。
- 市場開発: タイプ別、エンドユーザー別、地域別の有利な新興地域に関する包括的情報。
- 市場の多様化: 世界の医療用分析試験サービス市場における新サービス、成長地域、最近の動向に関する詳細な情報。
- 競合評価: 世界の医療用分析試験サービス市場における主要企業の市場シェア、成長戦略、収益分析、サービスについて詳細に評価します。

❖ レポートの目次 ❖

1 INTRODUCTION 47
1.1 STUDY OBJECTIVES 47
1.2 MARKET DEFINITION 47
1.2.1 INCLUSIONS & EXCLUSIONS 47
1.3 MARKETS COVERED 48
FIGURE 1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SEGMENTATION 48
1.3.1 YEARS CONSIDERED 49
1.4 CURRENCY CONSIDERED 49
TABLE 1 USD EXCHANGE RATES CONSIDERED, 2018–2021 49
1.5 STAKEHOLDERS 50
1.6 SUMMARY OF CHANGES 50
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH APPROACH 52
FIGURE 2 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: RESEARCH DESIGN 52
2.1.1 SECONDARY RESEARCH 52
2.1.1.1 Key data from secondary sources 53
2.1.2 PRIMARY DATA 54
FIGURE 3 PRIMARY SOURCES 54
2.1.2.1 Key data from primary sources 55
2.1.2.2 Insights from primary experts 55
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 56
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 56
2.2 MARKET SIZE ESTIMATION 57
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 57
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION 58
FIGURE 9 TOP-DOWN APPROACH 59
FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
FIGURE 11 CAGR PROJECTIONS 60
2.3 DATA TRIANGULATION APPROACH 62
FIGURE 12 DATA TRIANGULATION METHODOLOGY 62
2.4 MARKET SHARE ESTIMATION 63
2.5 STUDY ASSUMPTIONS 63
2.6 LIMITATIONS 63
2.6.1 METHODOLOGY-RELATED LIMITATIONS 64
2.6.2 SCOPE-RELATED LIMITATIONS 64

2.7 RISK ASSESSMENT 64
TABLE 2 RISK ASSESSMENT: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 64
3 EXECUTIVE SUMMARY 65
FIGURE 13 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 65
FIGURE 14 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 66
FIGURE 15 PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 67
FIGURE 16 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 68
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 69
4 PREMIUM INSIGHTS 70
4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW 70
FIGURE 18 GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH 70
4.2 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE AND COUNTRY (2021) 71
FIGURE 19 BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 71
4.3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 72
FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 72
4.4 REGIONAL MIX: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2020–2027) 73
FIGURE 21 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2020–2027) 73
4.5 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEVELOPED VS. DEVELOPING MARKETS (2022 VS. 2027) 73
FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 73
5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
FIGURE 23 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 74
5.2.1 DRIVERS 75
5.2.1.1 Growing focus on analytical testing of biologics & biosimilars 75
TABLE 3 PATENT EXPIRY OF BEST-SELLING BIOLOGICS 75
5.2.1.2 Increasing outsourcing of analytical testing by pharmaceutical and medical device companies 76
5.2.1.3 Increasing number of clinical trials 76
FIGURE 24 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2002–2021) 77
5.2.1.4 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry 77
FIGURE 25 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2001–2021 77
5.2.1.5 Rising acceptance of quality-by-design approach in pharma research and manufacturing 78
TABLE 4 IMPACT ANALYSIS: DRIVERS 78
5.2.2 RESTRAINTS 79
5.2.2.1 Shortage of skilled professionals 79
5.2.2.2 Increasing pressure on market players due to rising costs and market competition 79
TABLE 5 IMPACT ANALYSIS: RESTRAINTS 80
5.2.3 OPPORTUNITIES 80
5.2.3.1 Adoption of new techniques and technologies 80
5.2.3.2 Growing focus on emerging markets 81
TABLE 6 IMPACT ANALYSIS: OPPORTUNITIES 81
5.2.4 CHALLENGES 82
5.2.4.1 Specific requirements for innovative formulations and medical devices 82
5.2.4.2 Need to improve sensitivity of bioanalytical methods 82
TABLE 7 IMPACT ANALYSIS: CHALLENGES 83
5.3 KEY CONFERENCES & EVENTS, 2022–2023 83
TABLE 8 HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS 83
5.4 INDUSTRY TRENDS 84
5.4.1 EXPANDING SERVICE PORTFOLIO AND MARKET REACH THROUGH ACQUISITIONS 84
TABLE 9 MAJOR ACQUISITIONS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 84
5.5 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 10 PORTER’S FIVE FORCES ANALYSIS 85
5.5.1 THREAT FROM NEW ENTRANTS 85
5.5.2 BARGAINING POWER OF SUPPLIERS 85
5.5.3 INTENSITY OF COMPETITIVE RIVALRY 85
5.5.4 BARGAINING POWER OF BUYERS 86
5.5.5 THREAT FROM SUBSTITUTES 86
5.6 KEY STAKEHOLDERS & BUYING CRITERIA 87
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 87
5.6.2 BUYING CRITERIA 88
TABLE 12 KEY BUYING CRITERIA FOR END USERS 88
5.7 CASE STUDY ANALYSIS 88
5.7.1 CASE STUDY 1: WELLSTAT THERAPEUTICS & ALMAC GROUP 88
5.7.2 CASE STUDY 2: METHOD DEVELOPMENT CASE STUDY 88
5.8 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 13 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
5.9 REGULATORY ANALYSIS 89
TABLE 14 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS 90
TABLE 15 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES 91
5.9.1 NORTH AMERICA 91
5.9.2 EUROPE 92
TABLE 16 DEVELOPMENT OF GLP ACROSS COUNTRIES 92
TABLE 17 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES 93
5.9.3 ASIA PACIFIC 93
5.10 TECHNOLOGY ANALYSIS 94
5.10.1 LIMS (LABORATORY INFORMATION MANAGEMENT SYSTEMS) PLATFORMS 94
5.10.2 INTACT MOLECULAR WEIGHT BY MASS SPECTROMETRY 94
5.10.3 MULTI-ATTRIBUTE METHODS BASED ON PEPTIDE MAPPING BY LC-UV-MS 94
5.10.4 TETRACYCLINE-ENABLED SELF-SILENCING ADENOVIRUS (TESSA) 94
5.11 VALUE CHAIN ANALYSIS: DRUG DEVELOPMENT & MANUFACTURING PROCESS 95
FIGURE 28 VALUE CHAIN ANALYSIS: DRUG DEVELOPMENT & MANUFACTURING PROCESS 95
5.12 ECOSYSTEM ANALYSIS 95
TABLE 18 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM 96
5.13 PATENT ANALYSIS: BIOANALYTICAL TESTING 96
5.13.1 PATENT PUBLICATION TRENDS FOR BIOANALYTICAL TESTING 96
FIGURE 29 PATENT PUBLICATION TRENDS (2011–OCTOBER 2022) 97
5.13.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 97
FIGURE 30 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR BIOANALYTICAL TESTING (JANUARY 2011–OCTOBER 2022) 98
FIGURE 31 TOP APPLICANT JURISDICTIONS FOR BIOANALYTICAL TESTING PATENTS (JANUARY 2011–OCTOBER 2022) 99
TABLE 19 LIST OF PATENTS/PATENT APPLICATIONS IN BIOANALYTICAL TESTING MARKET, 2021–2022 99
6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE 100
6.1 INTRODUCTION 101
TABLE 20 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 101
6.2 BIOANALYTICAL TESTING SERVICES 101
TABLE 21 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 102
TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
6.2.1 CELL-BASED ASSAYS 103
6.2.1.1 Growing adoption of high-content screening for cytotoxicity testing to fuel growth 103
TABLE 23 CELL-BASED ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
6.2.2 VIROLOGY TESTING 105
6.2.2.1 Increasing outbreaks of viral diseases to drive market 105
TABLE 24 VIROLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
6.2.3 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING 107
6.2.3.1 Increasing requirement for drug safety approvals to support market 107
TABLE 25 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 108
6.2.4 BIOMARKER TESTING 108
6.2.4.1 Rising need for specialized drug development to drive market 108
TABLE 26 BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
6.2.5 PHARMACOKINETIC TESTING 110
6.2.5.1 Increasing number of clinical trials for drug development to propel growth 110
TABLE 27 PHARMACOKINETIC TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
6.2.6 OTHER BIOANALYTICAL TESTING SERVICES 111
TABLE 28 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 112
6.3 PHYSICAL CHARACTERIZATION 112
TABLE 29 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 30 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
6.3.1 LASER PARTICLE SIZE ANALYSIS 114
6.3.1.1 Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market 114
TABLE 31 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
6.3.2 THERMAL ANALYSIS 116
6.3.2.1 Advancements in thermal analysis techniques to support growth 116
TABLE 32 THERMAL ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
6.3.3 IMAGE ANALYSIS 117
6.3.3.1 Growing complexity of biological structures to contribute to growth 117
TABLE 33 IMAGE ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118
6.3.4 SURFACE AREA ANALYSIS 118
6.3.4.1 Growing need of surface analysis to streamline drug development processes to fuel growth 118
TABLE 34 SURFACE AREA ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 119

6.3.5 OTHER PHYSICAL CHARACTERIZATION ANALYSIS SERVICES 120
TABLE 35 OTHER PHYSICAL CHARACTERIZATION ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
6.4 METHOD DEVELOPMENT & VALIDATION 121
TABLE 36 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 37 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122
6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION 122
6.4.1.1 Growing development of parenterally administered drugs and biologic products to drive market 122
TABLE 38 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION 124
6.4.2.1 Rising emphasis on impurity testing to boost market 124
TABLE 39 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
6.4.3 STABILITY-INDICATING METHOD VALIDATION 125
6.4.3.1 Need to ensure safety and efficacy of therapeutic drugs to spur growth 125
TABLE 40 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
6.4.4 CLEANING VALIDATION 126
6.4.4.1 Growing need to evaluate cleaning practices and ensure complete decontamination to fuel growth 126
TABLE 41 CLEANING VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 127
6.4.5 ANALYTICAL STANDARD CHARACTERIZATION 128
6.4.5.1 Growing importance of analytical standard characterization in drug development to support market 128
TABLE 42 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
6.4.6 TECHNICAL CONSULTING 129
6.4.6.1 Need for regulatory approvals for drug development to drive market 129
TABLE 43 TECHNICAL CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130
6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES 130
TABLE 44 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
6.5 RAW MATERIAL TESTING 131
TABLE 45 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 46 RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 133
6.5.1 COMPLETE COMPENDIAL TESTING 133
6.5.1.1 Need to determine efficacy and safety of therapeutic products to drive growth 133
TABLE 47 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134
6.5.2 CONTAINER TESTING 134
6.5.2.1 Need to optimize sealing and evaluate temperature impact to fuel growth 134
TABLE 48 CONTAINER TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
6.5.3 HEAVY METAL TESTING 135
6.5.3.1 Implementation of various techniques and technologies for heavy metal testing to aid growth 135
TABLE 49 HEAVY METAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
6.5.4 KARL FISCHER ANALYSIS 137
6.5.4.1 Need to check for water content in pharmaceutical products to support growth 137
TABLE 50 KARL FISCHER ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 137
6.5.5 WET CHEMISTRY ANALYSIS 138
6.5.5.1 Adoption of upcoming technologies to boost market 138
TABLE 51 WET CHEMISTRY ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
6.5.6 OTHER RAW MATERIAL TESTING SERVICES 139
TABLE 52 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
6.6 BATCH-RELEASE TESTING SERVICES 140
TABLE 53 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 54 BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142
6.6.1 DISSOLUTION TESTING 142
6.6.1.1 Wide usage of dissolution testing in formulation development and manufacturing to drive growth 142
TABLE 55 DISSOLUTION TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 143
6.6.2 ELEMENTAL IMPURITY TESTING 144
6.6.2.1 Need to minimize cost of in-house analysis and labor to fuel growth 144
TABLE 56 ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
6.6.3 DISINTEGRATION TESTING 145
6.6.3.1 Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth 145
TABLE 57 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA 146
TABLE 58 DISINTEGRATION TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
6.6.4 HARDNESS TESTING 147
6.6.4.1 Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth 147
TABLE 59 HARDNESS TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
6.6.5 FRIABILITY TESTING 149
6.6.5.1 Need to measure resistance of tablets and granules to abrasion to support market 149
TABLE 60 FRIABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149
6.6.6 OTHER BATCH-RELEASE TESTING SERVICES 150
TABLE 61 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
6.7 STABILITY TESTING 151
TABLE 62 STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 63 STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
6.7.1 DRUG SUBSTANCE STABILITY TESTING 152
6.7.1.1 Regulatory requirements for drug approval to drive market 152
TABLE 64 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
6.7.2 FORMULATION EVALUATION STABILITY TESTING 153
6.7.2.1 Need to analyze and predict shelf life of products to drive demand 153
TABLE 65 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 154
6.7.3 ACCELERATED STABILITY TESTING 154
6.7.3.1 Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth 154
TABLE 66 ACCELERATED STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155
6.7.4 PHOTOSTABILITY TESTING 155
6.7.4.1 Need for robust photostability testing process to ensure product quality and safety to drive adoption 155
TABLE 67 PHOTOSTABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156
6.7.5 COMPARATOR STABILITY TESTING 157
6.7.5.1 Need to assess relative bioequivalence, efficacy, and safety of products to boost market 157
TABLE 68 COMPARATOR STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
6.7.6 OTHER STABILITY TESTING SERVICES 158
TABLE 69 OTHER STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
6.8 MICROBIAL TESTING 159
TABLE 70 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 71 MICROBIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160

6.8.1 MICROBIAL LIMIT TESTING 160
6.8.1.1 Need to determine whether products comply with compendial specifications for microbial quality to boost adoption 160
TABLE 72 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING 161
TABLE 73 MICROBIAL LIMIT TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 162
6.8.2 STERILITY TESTING 162
6.8.2.1 Rising development of parenteral preparations and immunological products to drive market 162
TABLE 74 STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 163
6.8.3 ENDOTOXIN TESTING 163
6.8.3.1 Need to standardize procedures and follow regulatory guidelines to support demand 163
TABLE 75 ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 164
6.8.4 PRESERVATIVE EFFICACY TESTING 165
6.8.4.1 Need to ensure product safety for product approval to support growth 165
TABLE 76 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 166
6.8.5 WATER TESTING 166
6.8.5.1 Growing development of pharmaceutical drugs to drive market 166
TABLE 77 STANDARDIZED LIMITS FOR WATER TESTING 167
TABLE 78 WATER TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 167
6.8.6 OTHER MICROBIAL TESTING SERVICES 168
TABLE 79 OTHER MICROBIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 169
6.9 ENVIRONMENTAL MONITORING SERVICES 169
TABLE 80 ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 81 ENVIRONMENTAL MONITORING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 170
6.9.1 AIR TESTING 171
6.9.1.1 Need to ensure safe environment for healthcare product development to drive market 171
TABLE 82 PURITY CLASSES FOR PARTICLES, WATER, AND OIL IN COMPRESSED AIR 171
TABLE 83 AIR TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 172
6.9.2 WASTEWATER TESTING SERVICES 172
6.9.2.1 Need to minimize water contamination to support demand 172
TABLE 84 STANDARDS FOR WASTEWATER QUALITY 173
TABLE 85 WASTEWATER TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 174
6.9.3 OTHER ENVIRONMENTAL MONITORING SERVICES 174
TABLE 86 OTHER ENVIRONMENTAL MONITORING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 175
7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER 176
7.1 INTRODUCTION 177
TABLE 87 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 177
7.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 177
7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH 177
FIGURE 32 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2019–2021 178
TABLE 88 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 179
7.3 MEDICAL DEVICE COMPANIES 179
7.3.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH 179
TABLE 89 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 181
7.4 CONTRACT RESEARCH ORGANIZATIONS 181
7.4.1 GROWING NUMBER OF CLINICAL TRIALS TO BOOST MARKET 181
TABLE 90 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR CROS, BY COUNTRY, 2020–2027 (USD MILLION) 182
8 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION 183
8.1 INTRODUCTION 184
FIGURE 33 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC SNAPSHOT (2021) 184
TABLE 91 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 185
8.2 NORTH AMERICA 185
FIGURE 34 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA (2019) 186
FIGURE 35 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 187
TABLE 92 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 187
TABLE 93 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 94 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 95 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 96 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 97 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 98 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 99 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 100 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 101 NORTH AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 102 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 192
8.2.1 US 192
8.2.1.1 High number of pre-registration drugs in pipeline to drive market 192
FIGURE 36 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2019) 193
TABLE 103 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 104 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 105 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 106 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 107 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 108 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 109 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 110 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 111 US: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 112 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 198
8.2.2 CANADA 198
8.2.2.1 Well-established CROs to support market growth 198
TABLE 113 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2020) 199
TABLE 114 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 115 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 116 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 117 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 118 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 119 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 120 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 121 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 122 CANADA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 123 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 204
8.3 EUROPE 204
TABLE 124 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 205
TABLE 125 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 126 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 127 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 128 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 129 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 130 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 131 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 132 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 133 EUROPE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 210
TABLE 134 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 210
8.3.1 GERMANY 210
8.3.1.1 Government support and flexible labor laws to make Germany favorable location for clinical trials 210
TABLE 135 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 136 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 137 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 138 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 139 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 140 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 141 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 142 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 143 GERMANY: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 144 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 216

8.3.2 FRANCE 216
8.3.2.1 Government regulations in France to drive market 216
TABLE 145 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 146 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 147 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 148 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 149 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 150 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 151 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 152 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 153 FRANCE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 154 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 221
8.3.3 UK 221
8.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to support growth 221
TABLE 155 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 156 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 157 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 223
TABLE 158 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 223
TABLE 159 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 224
TABLE 160 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 224
TABLE 161 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 162 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 163 UK: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 164 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 226
8.3.4 ITALY 226
8.3.4.1 Low drug approval time in Italy to drive growth 226
TABLE 165 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 227
TABLE 166 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 227
TABLE 167 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 168 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 169 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 170 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 171 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 172 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 173 ITALY: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 231
TABLE 174 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 231
8.3.5 SWITZERLAND 231
8.3.5.1 Large and growing pharma production volume to drive demand for analytical testing services 231
TABLE 175 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 232
TABLE 176 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 177 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 178 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 179 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 180 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 181 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 182 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 183 SWITZERLAND: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 184 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 237
8.3.6 SPAIN 237
8.3.6.1 Rising R&D expenditure to boost growth 237
TABLE 185 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 186 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 187 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 188 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 189 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 240
TABLE 190 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 240
TABLE 191 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 192 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 193 SPAIN: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 242
TABLE 194 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 242
8.3.7 REST OF EUROPE (ROE) 242
TABLE 195 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 243
TABLE 196 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 244
TABLE 197 REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 244
TABLE 198 REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 245
TABLE 199 REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 245
TABLE 200 REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 201 REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 202 REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 203 REST OF EUROPE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 204 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 248

8.4 ASIA PACIFIC (APAC) 248
FIGURE 37 ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT 249
TABLE 205 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 250
TABLE 206 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 250
TABLE 207 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 208 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 209 ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 252
TABLE 210 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 252
TABLE 211 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 212 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 213 ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 214 ASIA PACIFIC: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 215 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 255
8.4.1 CHINA 255
8.4.1.1 Low manufacturing cost of medicines to drive demand 255
TABLE 216 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 256
TABLE 217 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 256
TABLE 218 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 257
TABLE 219 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 257
TABLE 220 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 221 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 222 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 259
TABLE 223 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 259
TABLE 224 CHINA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 260
TABLE 225 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 260
8.4.2 JAPAN 260
8.4.2.1 Rising geriatric population to support market 260
TABLE 226 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 261
TABLE 227 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 262
TABLE 228 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 262
TABLE 229 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 230 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 231 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 232 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 233 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 265
TABLE 234 JAPAN: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 265
TABLE 235 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 266
8.4.3 INDIA 266
8.4.3.1 Increasing number of clinical trials to drive market growth 266
TABLE 236 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 267
TABLE 237 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 267
TABLE 238 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 239 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 240 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 269
TABLE 241 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 269
TABLE 242 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 270
TABLE 243 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 270
TABLE 244 INDIA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 271
TABLE 245 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 271
8.4.4 AUSTRALIA 271
8.4.4.1 Large number of research institutes to make Australia favorable location for drug discovery 271
TABLE 246 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 247 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 248 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 273
TABLE 249 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 273
TABLE 250 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 274
TABLE 251 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 274
TABLE 252 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 253 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 254 AUSTRALIA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 276
TABLE 255 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 276
8.4.5 SOUTH KOREA 276
8.4.5.1 Growth in clinical trial activity to propel growth 276
TABLE 256 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 277
TABLE 257 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 278
TABLE 258 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 278
TABLE 259 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 279
TABLE 260 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 279
TABLE 261 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 262 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 263 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 264 SOUTH KOREA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 265 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 282
8.4.6 REST OF ASIA PACIFIC (ROAPAC) 282
TABLE 266 REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 283
TABLE 267 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 283
TABLE 268 REST OF ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 284
TABLE 269 REST OF ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 284
TABLE 270 REST OF ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 285
TABLE 271 REST OF ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 285
TABLE 272 REST OF ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 286
TABLE 273 REST OF ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 286
TABLE 274 REST OF ASIA PACIFIC: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 287
TABLE 275 REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 287

8.5 LATIN AMERICA 288
TABLE 276 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 288
TABLE 277 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 289
TABLE 278 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 289
TABLE 279 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 290
TABLE 280 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 290
TABLE 281 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 291
TABLE 282 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 291
TABLE 283 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 292
TABLE 284 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 292
TABLE 285 LATIN AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 293
TABLE 286 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 293
8.5.1 BRAZIL 293
8.5.1.1 Rising adoption of emerging medical technologies to drive market 293
TABLE 287 BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 294
TABLE 288 BRAZIL: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 295
TABLE 289 BRAZIL: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 295
TABLE 290 BRAZIL: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 296
TABLE 291 BRAZIL: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 296
TABLE 292 BRAZIL: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 297
TABLE 293 BRAZIL: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 297
TABLE 294 BRAZIL: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 298
TABLE 295 BRAZIL: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 298
TABLE 296 BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 299
8.5.2 MEXICO 299
8.5.2.1 Government initiatives and robust supply to drive market 299
TABLE 297 MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 300
TABLE 298 MEXICO: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 300
TABLE 299 MEXICO: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 301
TABLE 300 MEXICO: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 301
TABLE 301 MEXICO: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 302
TABLE 302 MEXICO: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 302
TABLE 303 MEXICO: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 303
TABLE 304 MEXICO: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 303
TABLE 305 MEXICO: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 304
TABLE 306 MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 304
8.5.3 REST OF LATIN AMERICA 304
TABLE 307 REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 305
TABLE 308 REST OF LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 305
TABLE 309 REST OF LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 306
TABLE 310 REST OF LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 306
TABLE 311 REST OF LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 307
TABLE 312 REST OF LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 307
TABLE 313 REST OF LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 308
TABLE 314 REST OF LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 308
TABLE 315 REST OF LATIN AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 309
TABLE 316 REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 309
8.6 MIDDLE EAST & AFRICA 309
8.6.1 INCREASING INVESTMENT OPPORTUNITIES FOR DOMESTIC MANUFACTURING OF MEDICAL DEVICES TO DRIVE GROWTH 309
TABLE 317 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 310
TABLE 318 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 311
TABLE 319 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 311
TABLE 320 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 312
TABLE 321 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 312
TABLE 322 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 313
TABLE 323 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 313
TABLE 324 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 314
TABLE 325 MIDDLE EAST & AFRICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 314
TABLE 326 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 315
9 COMPETITIVE LANDSCAPE 316
9.1 INTRODUCTION 316
9.2 STRATEGIES ADOPTED BY KEY PLAYERS 316
9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 317
9.3 REVENUE SHARE ANALYSIS 318
FIGURE 38 REVENUE ANALYSIS FOR KEY PLAYERS, 2016–2021 318
9.4 MARKET SHARE ANALYSIS 319
FIGURE 39 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SHARE,
BY KEY PLAYER, 2021 319
TABLE 327 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET:
DEGREE OF COMPETITION 319
9.5 COMPANY EVALUATION QUADRANT 320
9.5.1 STARS 320
9.5.2 PERVASIVE PLAYERS 320
9.5.3 EMERGING LEADERS 321
9.5.4 PARTICIPANTS 321
FIGURE 40 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION QUADRANT (2021) 321
9.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS (2021) 322
9.6.1 PROGRESSIVE COMPANIES 322
9.6.2 DYNAMIC COMPANIES 322
9.6.3 STARTING BLOCKS 322
9.6.4 RESPONSIVE COMPANIES 322
FIGURE 41 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET:
SME/START-UP COMPANY EVALUATION MATRIX, 2021 323
9.7 COMPETITIVE BENCHMARKING 324
TABLE 328 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET:
DETAILED LIST OF SMALL & MEDIUM-SIZED PLAYERS 324
9.8 COMPANY FOOTPRINT 325
TABLE 329 COMPANY FOOTPRINT (20 COMPANIES) 325
TABLE 330 COMPANY SERVICE FOOTPRINT (20 COMPANIES) 326
TABLE 331 COMPANY END-USER FOOTPRINT (20 COMPANIES) 327
TABLE 332 COMPANY REGIONAL FOOTPRINT (20 COMPANIES) 328
9.9 COMPETITIVE SITUATIONS AND TRENDS 329
9.9.1 SERVICE LAUNCHES & APPROVALS 329
TABLE 333 SERVICE LAUNCHES (2019–OCTOBER 2022) 329
9.9.2 DEALS 329
TABLE 334 DEALS (2019–OCTOBER 2022) 329
TABLE 335 OTHER DEVELOPMENTS (2019–OCTOBER 2022) 331
10 COMPANY PROFILES 332
(Business Overview, Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS 332
10.1.1 EUROFINS SCIENTIFIC 332
FIGURE 42 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 333
10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS 336
FIGURE 43 LABORATORY CORPORATION OF AMERICA HOLDINGS:
COMPANY SNAPSHOT (2021) 337
10.1.3 WUXI APPTEC 340
FIGURE 44 WUXI APPTEC: COMPANY SNAPSHOT (2021) 341
10.1.4 CHARLES RIVER LABORATORIES 345
FIGURE 45 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021) 346
10.1.5 SGS S.A. 350
FIGURE 46 SGS S.A.: COMPANY SNAPSHOT (2021) 351
10.1.6 THERMO FISHER SCIENTIFIC INC. 355
TABLE 341 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 355
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 356
10.1.7 MEDPACE HOLDINGS 358
FIGURE 48 MEDPACE HOLDINGS: COMPANY SNAPSHOT (2021) 359
10.1.8 SARTORIUS AG 360
TABLE 343 SARTORIUS AG: BUSINESS OVERVIEW 360
FIGURE 49 SARTORIUS AG: COMPANY SNAPSHOT (2021) 361
10.1.9 INTERTEK GROUP PLC 363
TABLE 344 INTERTEK GROUP PLC: BUSINESS OVERVIEW 363
FIGURE 50 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021) 364
10.1.10 MERCK KGAA 368
TABLE 345 MERCK KGAA: BUSINESS OVERVIEW 368
FIGURE 51 MERCK KGAA: COMPANY SNAPSHOT (2021) 369
10.1.11 SOURCE BIOSCIENCE 371
TABLE 346 SOURCE BIOSCIENCE: BUSINESS OVERVIEW 371
FIGURE 52 SOURCE BIOSCIENCE: COMPANY SNAPSHOT (2021) 372
10.1.12 ICON PLC 374
TABLE 347 ICON PLC: BUSINESS OVERVIEW 374
FIGURE 53 ICON PLC: COMPANY SNAPSHOT (2021) 374
10.1.13 ALS LIFE SCIENCES 377
TABLE 348 ALS LIFE SCIENCES: BUSINESS OVERVIEW 377
FIGURE 54 ALS LIFE SCIENCES: COMPANY SNAPSHOT (2022) 378
10.1.14 FRONTAGE LABORATORIES, INC. 380
TABLE 349 FRONTAGE LABORATORIES, INC.: BUSINESS OVERVIEW 380
FIGURE 55 FRONTAGE LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 381
10.1.15 STERIS PLC 384
TABLE 350 STERIS PLC: BUSINESS OVERVIEW 384
FIGURE 56 STERIS PLC: COMPANY SNAPSHOT (2022) 385
10.1.16 IQVIA INC. 387
FIGURE 57 IQVIA: COMPANY SNAPSHOT (2021) 388
10.1.17 ELEMENT MATERIALS TECHNOLOGY 390
TABLE 352 ELEMENT MATERIALS TECHNOLOGY: BUSINESS OVERVIEW 390
10.1.18 PACE ANALYTICAL SERVICES 392
TABLE 353 PACE ANALYTICAL SERVICES: BUSINESS OVERVIEW 392
10.1.19 ALMAC GROUP 396
TABLE 354 ALMAC GROUP: BUSINESS OVERVIEW 396
10.1.20 ABSORPTION SYSTEMS 398
TABLE 355 ABSORPTION SYSTEMS: BUSINESS OVERVIEW 398
10.2 OTHER PLAYERS 399
10.2.1 SYNEOS HEALTH INC. 399
10.2.2 PAREXEL INTERNATIONAL CORPORATION 400
10.2.3 LGC LIMITED 401
10.2.4 CELERION 402
10.2.5 BIOAGILYTIX LABS 402
*Details on Business Overview, Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 403
11.1 INSIGHTS FROM INDUSTRY EXPERTS 403
11.2 DISCUSSION GUIDE 404
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 410
11.4 CUSTOMIZATION OPTIONS 412
11.5 RELATED REPORTS 412
11.6 AUTHOR DETAILS 413

★調査レポート[世界の医療用分析試験サービス市場(~2027年):種類別(バイオマーカー試験、安定性試験、原材料試験、バッチリリース試験、洗浄検証)、エンドユーザー別(製薬企業、医療機器企業、CRO)] (コード:AST4341-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の医療用分析試験サービス市場(~2027年):種類別(バイオマーカー試験、安定性試験、原材料試験、バッチリリース試験、洗浄検証)、エンドユーザー別(製薬企業、医療機器企業、CRO)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆